|
|
||
|
Minrad International
Download PDF Members: MINRAD INTERNATIONAL, INC. is an innovator in acute care medical devices and pharmaceuticals. The company’s medical device products incorporate patented real time image-guidance technologies that enable medical professionals to improve the accuracy of interventional procedures and provide a significant reduction in radiation exposure for both patients and medical professionals. MINRAD’s present pharmaceutical products are generic inhalation anesthetics that are primarily used for surgical interventions. However, a patentable drug/drug delivery system is under development (see Conscious Sedation below). The company presently holds twelve patents in the areas of image-guided medical devices and anesthesia and analgesia, and has six additional patents pending. Most of its revenue is presently generated through the company’s pharmaceutical partners, including but not limited to: Baxter, E. Merck, Laboratories PiSA, Nicholas Piramal, Novartis, Panion BF Laboratories and RxElite. In the fourth quarter, the company will introduce a second generation of its image-guided medical technology. Anesthesia & Analgesia In December 2000, MINRAD acquired the assets of Celltech Medeva’s inhalation anesthetic business and modern manufacturing facility in Bethlehem, Pennsylvania. MINRAD produces two inhalation anesthetics: enflurane and isoflurane in the facility, which they sell, to leading acute care pharmaceutical companies around the world. The acquisition reunited Messer, Burns and McNeirney with Dr. Ross Terrell, the Vice President of Research of the subsidiary, with whom they had collaborated in pioneering the introduction of modern halogenated ethers as inhalant anesthetics while with the BOC Health Care Group. Dr. Terrell, who remains an active Research Fellow with MINRAD, was the inventor of enflurane, isoflurane and desflurane; and was acknowledged by the Pharmaceutical Manufacturer’s Association (“PMA”) as Man of the Year in 1991. Since the acquisition, MINRAD has sharply reduced the manufacturing costs in the facility, and is presently re-tooling the facility to allow the manufacture of sevoflurane (process patent, Terrell, issued). In this regard, the company anticipates filing an Abbreviated New Drug Application (“ANDA”) with the FDA in the fourth quarter.
This page has been viewed 278 times since April 2007, the link to the organisation's website has been followed 47 times Recent Search Terms used to find this page: medeva isofluran | nicholas pharma sevoflurane | minrad piramal acquired | Medeva Enflurane | app pharmaceuticals isoflurane | NPIL minrad sevoflurane | Minrad and Nicholas Piramal | minrad.com | nicholas piramal isoflurane | minrad desflurane anda 2008 | . Search for more companies in Orchard Park Search for more companies in New York This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Minrad International | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
| Nothing in this website should be used in
place of personal medical advice from your own qualified medical
practitioner. |
All rights reserved. All other trademarks recognized. |
|
